J. Goldman & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

J. Goldman & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-55,000	Closed	-$4.53M	–	471
2024 Q2	$4.53M	Buy	+55,000	New	+$4.58M	0.13%	178
2024 Q1	–	Sell	-32,500	Closed	-$3.13M	–	422
2023 Q4	$3.13M	Buy	+32,500	New	+$2.88M	0.13%	156
2020 Q3	–	Sell	-8,600	Closed	-$1.06M	–	311
2020 Q2	$1.06M	Buy	+8,600	New	+$855K	0.07%	192
2016 Q2	–	Sell	-60,000	Closed	-$4.95M	–	330
2016 Q1	$4.95M	Buy	+60,000	New	+$4.88M	0.31%	94
2014 Q3	–	Sell	-50,000	Closed	-$3.13M	–	280
2014 Q2	$3.13M	Buy	+50,000	New	+$3.02M	0.23%	115

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

J. Goldman & Co's BMRN Position: Q3 2024 in Review

J. Goldman & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 31,701 shares — an estimated $2.61M sold.

J. Goldman & Co first reported a position in BMRN in Q1 2016 and held it in 7 quarters. The position peaked at $11.6M in Q1 2024. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

J. Goldman & Co reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
J. Goldman & Co sold 31,701 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $2.61M.
J. Goldman & Co first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 7 quarters.
J. Goldman & Co's BioMarin Pharmaceuticals position peaked at $11.6M in Q1 2024.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.